Dr. Siegelin is a physician-scientist, investigating tumor cell metabolism in malignant glial brain tumors with the goal to overcome resistance to cell death and to identify novel treatment regimens for glioblastoma. Dr. Siegelin's lab has significant experience on establishing novel drug combinations for recalcitrant tumors and the elucidation of their mechanisms at the preclinical level, as demonstrated in the following references (1-4). Dr. Siegelin's major goal is to significantly contribute to the field of neuro-oncology with the goal to identify and translate promising therapeutic drug regimens into the clinic to help patients, their families and the society to combat this detrimental disease.
1. Nguyen TTT, Shang E, Shu C, Kim S, Mela A, Humala N, Mahajan A, Yang HW, Akman HO, Quinzii CM, Zhang G, Westhoff MA, Karpel-Massler G, Bruce JN, Canoll P, Siegelin MD. Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. Nat Commun. 2021 Sep 1;12(1):5203. doi: 10.1038/s41467-021-25501-x. PMID: 34471141
2. Karpel-Massler G, Chiaki Tsuge Ishida, Elena Bianchetti, Yiru Zhang, Chang Shu, Takashi Tsujiuchi, Matei A. Banu, Franklin Garcia, Kevin A. Roth, Jeffrey N. Bruce, Peter Canoll and Siegelin MD. Induction of Synthetic Lethality in IDH1-Mutated Gliomas through inhibition of Bcl-xL. Nat Commun. 2017 Oct 20;8(1):1067. doi: 10.1038/s41467-017-00984-9.
3. Nguyen T, Zhang Y, Shang E, Shu C, Torrini C, Zhao J, Bianchetti E, Mela A, Humala N, Mahajan A, Harmanci AO, Lei Z, Maienschein-Cline M, Quinzii CM, Westhoff MA, Karpel-Massler G, Bruce JN, Canoll P, Siegelin MD. HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. J Clin Invest. 2020 Apr 21. pii: 129049. doi: 10.1172/JCI129049.
4. Zhang Y, Nguyen TTT, Shang E, Mela A, Humala N, Mahajan A, Zhao J, Shu C, Torrini C, Sanchez-Quintero MJ, Kleiner G, Bianchetti E, Westhoff MA, Quinzii CM, Karpel-Massler G, Bruce JN, Canoll P, Siegelin MD. MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma. Cancer Res. 2020 Jan 1;80(1):30-43. doi: 10.1158/0008-5472.CAN-19-1389.
